U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H14NO3.Na
Molecular Weight 279.2663
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOLMETIN SODIUM ANHYDROUS

SMILES

[Na+].CN1C(CC([O-])=O)=CC=C1C(=O)C2=CC=C(C)C=C2

InChI

InChIKey=QGUALMNFRILWRA-UHFFFAOYSA-M
InChI=1S/C15H15NO3.Na/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18;/h3-8H,9H2,1-2H3,(H,17,18);/q;+1/p-1

HIDE SMILES / InChI
Tolmetin is a nonsteroidal anti-inflammatory agent. It was marketed as Tolectin in USA. TOLECTIN (tolmetin sodium) is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. TOLECTIN is indicated in the treatment of acute flares and the long-term management of the chronic disease. TOLECTIN is also indicated for treatment of juvenile rheumatoid arthritis. The mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Tolmetin sodium

Approved Use

Carefully consider the potential benefits and risks of tolmetin sodium capsules and other treatment options before deciding to use tolmetin sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age.

Launch Date

1976
Primary
Tolmetin sodium

Approved Use

Carefully consider the potential benefits and risks of tolmetin sodium capsules and other treatment options before deciding to use tolmetin sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Tolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin sodium capsules are indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age.

Launch Date

1976
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
29.3 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOLMETIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
50.5 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOLMETIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.83 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TOLMETIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Other AEs: Nausea, Dyspepsia...
Other AEs:
Nausea (11%)
Dyspepsia (3-9)
Distress gastrointestinal (3-9)
Abdominal pain (3-9)
Diarrhea (3-9)
Flatulence (3-9)
Vomiting (3-9)
Constipation (1-3)
Gastritis (1-3)
Peptic ulcer (1-3)
Headache (3-9)
Asthenia (3-9)
Chest pain (1-3)
Blood pressure increased (3-9)
Edema (3-9)
Dizziness (3-9)
Drowsiness (3-9)
Depression (1-3)
Weight gain (3-9)
Weight loss (3-9)
Skin irritation (1-3)
Tinnitus (1-3)
Visual disturbance (1-3)
Blood urea nitrogen increased (1-3)
Urinary tract infection (1-3)
Gastrointestinal ulcer bleeding (<1%)
Bleeding gastrointestinal (<1%)
Perforation (<1%)
Glossitis (<1%)
Stomatitis (<1%)
Hepatitis (<1%)
Function liver abnormal (<1%)
Anaphylactoid reaction (<1%)
Fever (<1%)
Lymphadenopathy (<1%)
Serum sickness (<1%)
Hemolytic anemia (<1%)
Thrombocytopenia (<1%)
Granulocytopenia (<1%)
Agranulocytosis (<1%)
Urticaria (<1%)
Purpura (<1%)
Erythema multiforme (<1%)
Toxic epidermal necrolysis (<1%)
Hematuria (<1%)
Proteinuria (<1%)
Dysuria (<1%)
Renal failure (<1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Blood urea nitrogen increased 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Chest pain 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Constipation 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Depression 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Gastritis 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Peptic ulcer 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Skin irritation 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Tinnitus 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Urinary tract infection 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Visual disturbance 1-3
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Nausea 11%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Abdominal pain 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Asthenia 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Blood pressure increased 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Diarrhea 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Distress gastrointestinal 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Dizziness 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Drowsiness 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Dyspepsia 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Edema 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Flatulence 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Headache 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Vomiting 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Weight gain 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Weight loss 3-9
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Agranulocytosis <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Anaphylactoid reaction <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Bleeding gastrointestinal <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Dysuria <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Erythema multiforme <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Fever <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Function liver abnormal <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Gastrointestinal ulcer bleeding <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Glossitis <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Granulocytopenia <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Hematuria <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Hemolytic anemia <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Hepatitis <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Lymphadenopathy <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Perforation <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Proteinuria <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Purpura <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Renal failure <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Serum sickness <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Stomatitis <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Thrombocytopenia <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Toxic epidermal necrolysis <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Urticaria <1%
400 mg 3 times / day steady, oral (starting)
Dose: 400 mg, 3 times / day
Route: oral
Route: steady
Dose: 400 mg, 3 times / day
Sources:
unhealthy, adults
n = 800
Health Status: unhealthy
Condition: rheumatoid arthritis and osteoarthritis
Age Group: adults
Population Size: 800
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 20.5 uM]
yes [IC50 494 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
PubMed

PubMed

TitleDatePubMed
Immune hemolytic anemia associated with tolmetin and suprofen.
1989 Sep
Determination of nonsteroidal anti-inflammatory drugs in biological fluids by automatic on-line integration of solid-phase extraction and capillary electrophoresis.
2001 Feb
Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac.
2001 Jan 5
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.
2001 May-Jun
Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides.
2001 Nov 21
New hydrogel matrices containing an anti-inflammatory agent. Evaluation of in vitro release and photoprotective activity.
2002 Jan
Effect of experimental hypoalbuminemia on the plasma protein binding of tolmetin.
2002 Jul 19
Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible gastric nitric oxide synthase.
2002 Jun
Quantitation of tolmetin by high-performance liquid chromatography and method validation.
2003 Aug
Tolmetin and salicylate therapy in acute rheumatic fever: Comparison of clinical efficacy and side-effects.
2003 Dec
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study.
2003 Jun 2
Detection and disposition of tolmetin in the horse.
2003 Mar 26
Identification of coenzyme A-related tolmetin metabolites in rats: relationship with reactive drug metabolites.
2003 May
Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile.
2003 Nov
Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor.
2003 Oct
Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility.
2003 Oct 9
In vitro reactivity of carboxylic acid-CoA thioesters with glutathione.
2004 Jan
Hydrogen peroxide scavenging activity by non-steroidal anti-inflammatory drugs.
2005 Apr 29
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
I almost crossed over.
2005 Oct
Anti-inflammatory and immunosuppressive drugs and reproduction.
2006
Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons.
2006 Sep
In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs.
2007 Apr
One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm.
2007 Apr
Determination of non-steroidal anti-inflammatory drugs in urine by combining an immobilized carboxylated carbon nanotubes minicolumn for solid-phase extraction with capillary electrophoresis-mass spectrometry.
2007 Aug 3
In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems in different models of gastrointestinal injury.
2007 Jan
Potential antioxidant activity of celecoxib and amtolmetin guacyl: in vitro studies.
2007 Jan
Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport.
2007 Jan
Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin.
2007 Jan 31
Non-steroidal anti-inflammatory agents, tolmetin and sulindac attenuate quinolinic acid (QA)-induced oxidative stress in primary hippocampal neurons and reduce QA-induced spatial reference memory deficits in male Wistar rats.
2007 Mar 20
Studies on the metabolism of tolmetin to the chemically reactive acyl-coenzyme A thioester intermediate in rats.
2007 May
Improving adherence to medical regimens for juvenile rheumatoid arthritis.
2007 May 18
Modulation of dopaminergic neurotransmission in rat striatum upon in vitro and in vivo diclofenac treatment.
2008 Apr
Topical ocular delivery of NSAIDs.
2008 Jun
The effect of piroxicam on the formation of postoperative, intraabdominal adhesion in rats.
2008 Oct
Entrapment of ketorolac tromethamine in polymeric vehicle for controlled drug delivery.
2009 Nov
Sequential injection system for phospholipase A2 activity evaluation: studies on liposomes using an environment-sensitive fluorescent probe.
2009 Sep 15
Accuracy of rapid urease test in diagnosing Helicobacter pylori infection in patients using NSAIDs.
2010 Apr-Jun
Friedel-Crafts acylation of pyrroles and indoles using 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) as a nucleophilic catalyst.
2010 Dec 17
Control of encapsulation efficiency in polymeric microparticle system of tolmetin.
2010 Jan-Feb
Determination of actarit from human plasma for bioequivalence studies.
2010 Nov
Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites.
2010 Oct 28
Effect of ketorolac and diclofenac on the impairment of endothelium-dependent relaxation induced by reactive oxygen species in rabbit abdominal aorta.
2010 Sep
Identification of old drugs as potential inhibitors of HIV-1 integrase - human LEDGF/p75 interaction via molecular docking.
2012 Dec
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
2014 Jan
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Sample Use Guides

For the relief of rheumatoid arthritis or osteoarthritis, the recommended starting dose for adults is 400 mg three times daily (1200 mg daily), preferably including a dose on arising and a dose at bedtime. To achieve optimal therapeutic effect the dose should be adjusted according to the patient’s response after one or two weeks. Control is 15 usually achieved at doses of 600-1800 mg daily in divided doses (generally t.i.d.). Doses larger than 1800 mg/day have not been studied and are not recommended.
Route of Administration: Oral
Tolmetin inhibited the activity of human COX-1 and -2 with IC50 values of 0.35 and 0.82 uM, respectively
Name Type Language
TOLMETIN SODIUM ANHYDROUS
Common Name English
1H-PYRROLE-2-ACETIC ACID, 1-METHYL-5-(4-METHYLBENZOYL)-, SODIUM SALT (1:1)
Common Name English
Tolmetin sodium [WHO-DD]
Common Name English
1H-PYRROLE-2-ACETIC ACID, 1-METHYL-5-(4-METHYLBENZOYL)-, SODIUM SALT
Common Name English
SODIUM TOLMETIN
Common Name English
SODIUM 1-METHYL-5-P-TOLUOYLPYRROLE-2-ACETATE
Common Name English
Code System Code Type Description
CHEBI
9619
Created by admin on Fri Dec 15 15:54:55 GMT 2023 , Edited by admin on Fri Dec 15 15:54:55 GMT 2023
PRIMARY
CAS
35711-34-3
Created by admin on Fri Dec 15 15:54:55 GMT 2023 , Edited by admin on Fri Dec 15 15:54:55 GMT 2023
PRIMARY
FDA UNII
WL259637KX
Created by admin on Fri Dec 15 15:54:55 GMT 2023 , Edited by admin on Fri Dec 15 15:54:55 GMT 2023
PRIMARY
EPA CompTox
DTXSID2091546
Created by admin on Fri Dec 15 15:54:55 GMT 2023 , Edited by admin on Fri Dec 15 15:54:55 GMT 2023
PRIMARY
PUBCHEM
23665411
Created by admin on Fri Dec 15 15:54:55 GMT 2023 , Edited by admin on Fri Dec 15 15:54:55 GMT 2023
PRIMARY
ECHA (EC/EINECS)
252-687-3
Created by admin on Fri Dec 15 15:54:55 GMT 2023 , Edited by admin on Fri Dec 15 15:54:55 GMT 2023
PRIMARY